Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

NCT05367440 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

174

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Prostate Cancer

Interventions

DRUG: AZD5305
DRUG: Enzalutamide
DRUG: Abiraterone Acetate
DRUG: Darolutamide
DRUG: Apalutamide

Sponsor

AstraZeneca

Collaborators

[object Object]